Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1325-1334

  Saraceno, Rosita ^a   Bavetta, Mauro ^a   Zangrilli, Arianna ^a   Chiricozzi, Andrea ^a   Potenza, Concetta ^b   Chimenti, Sergio ^a   Chimenti, Maria Sole ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adalimumab; long term treatment; Plaque type psoriasis; Psoriatic arthritis; TNF

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO;

APPENDICITIS; ARTICLE; CELLULITIS; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; LONG TERM CARE; MELANOMA; NAIL PSORIASIS; NON MELANOMA SKIN CANCER; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84881532229     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.820701     Document Type: Article

References (54)

1. Chiricozzi A, Zhang S, Dattola A, et al. New insights into the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents 2012; 26(2): 165-70
2. Griffths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71 (Pubitemid 47069537)
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7 (Pubitemid 29418506)
4. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204 (Pubitemid 36398393)
5. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondyloarthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68(Suppl 2): ii1-44
6. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18: 297-304
7. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84
8. Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2000; 1: 27-39
9. Ortonne J-P, Orzechowski H-D, Rantanen T, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1-70
10. Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88
11. Humira (adalimumab) prescribing information [package insert]. Abbott Laboratories IL; North Chicago: 2012
12. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 1999; 58(Suppl 1): I70-2
13. Santora LC, Kaymakcalan Z, Sakorafas P, et al. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299: 119-29 (Pubitemid 34053400)
14. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79
15. Granneman RG, Zhang Y, Noertersheuser PA, et al. Pharmacokinetic/ pharmacodynamics (PK/ PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum 2003; 48: S140-1
16. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006t; 55(4): 598-606
17. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15 (Pubitemid 350298146)
18. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66 (Pubitemid 351239154)
19. Vena G A, Galluccio A, De Simone C, et al. A multicenter open-label study experiences on the response of psoriasis to adalimumab and effect of dose escalation in non-responders: the APHRODITE project. Int J Immunopathol Pharmacol 2009; 22(1): 227-33
20. Thaçi D, Ortonne J P, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/ betamethasone topical treatment in patient with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163(2): 402-11
21. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009; 68: 702-9
22. Gladman DD, Mease PJ, Choy E, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010; 12(3): R113
23. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89 (Pubitemid 41447111)
24. van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesion. Ann Rheum Dis 2010; 69: 394-9
25. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34(5): 1040-50 (Pubitemid 46774851)
26. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-75 (Pubitemid 47048857)
27. Gladman DD, Sampalis JS, Illouz O, Guérette B; ACCLAIM Study Investigators. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010; 37(9): 1898-906
28. Teoli M, Zangrilli A, Chimenti MS, et al. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol 2012; 2012: 823854
29. Van L, Modi SV, Yang DJ, et al. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008; 144: 804-6 (Pubitemid 351846889)
30. van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69: 624-5
31. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27 (Pubitemid 46899261)
32. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24(5): 530-4
33. Sánchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011; 25(5): 579-86
34. Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12(3): R117
35. Saraceno R, Pietroleonardo L, Mazzotta A, et al. TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013; 13(4): 469-73
36. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165(5): 1037-43
37. Piérard GE, Piérard-Franchimont C, Szepetiuk G, et al. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010; 10(8): 1197-208
38. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212(2): 123-7 (Pubitemid 43260727)
39. Papp K, Signorovitch J, Ramakrishnan K, et al. Effects of adalimumab versus placebo on risk of symptoms worsening in psoriasis and subsequent impacts on health-related quality of life. Analysis of pooled data from two randomized, double-blind, placebo-controlled, multicenter clinical trials. Clin Drug Investig 2011; 31: 51-60
40. Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the united states general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008; 6: 75
41. Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 66: e67-76
42. Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumb. Expert Opin Biol Ther 2010; 10(1): 133-52
43. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities. Am J Clin Dermatol 2011; 12(1): 51-62
44. Linder D, Sampogna F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012; 26(9): 1163-6
45. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis. A comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011; 12(5): 321-37
46. Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systemic review of the literature. Biologics 2009; 3: 303-18
47. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23.548 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72(4): 517-24
48. Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012; 30(5): 700-6
49. De Simone C, Sollena P, Coco V, et al. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases. G Ital Dermatol Venereol 2013; 148(2): 175-84
50. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59(7): 996-1001 (Pubitemid 351990997)
51. Michaëlsson G, Kajermo U, Michaëlsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153(6): 1243-4 (Pubitemid 41779595)
52. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63(2): 382-90
53. Nijsten T, Wakkee M. Psocare: Italy shows the way in postmarketing studies. Dermatology 2008; 217(4): 362-4
54. Sauzullo I, Mengoni F, Scrivo R, et al. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010; 14(7): 834-40